Suppr超能文献

与印片和流式DNA分析相比,组织切片中骨肉瘤的DNA显微分光光度测定法。

DNA microspectrophotometry of bone sarcomas in tissue sections as compared to imprint and flow DNA analysis.

作者信息

Bauer H C, Kreicbergs A, Tribukait B

出版信息

Cytometry. 1986 Nov;7(6):544-50. doi: 10.1002/cyto.990070608.

Abstract

The aim of the present study was to establish an upper limit of diploidy for microspectrophotometric (MSP) DNA measurements in sections of mesenchymal tissue analyzing DNA data of a large number of normal cell populations. The reliability of this upper limit of diploidy for discriminating between diploid and hyperploid bone sarcomas was tested by analyzing the same tumors by MSP in imprint preparations and flow cytometry (FCM). The median DNA value of control cells in tissue sections was given arbitrary value of DNA index (DI) 1.0, denoting the diploid DNA content. The proportion of cells with DNA values exceeding DI 1.25 (greater than DI 1.25) was determined for each normal cell population. The maximum percentage of cells with DNA values exceeding DI 1.25, encountered by analysis of 91 normal cell populations in tissue sections, was 31%. This percentage was set as an upper limit of diploidy. Hence, tumors with a higher percentage of cells greater than DI 1.25 were classified as hyperploid. When we applied this criterion, 31 of 36 sarcomas analyzed by MSP in tissue sections were hyperploid, which was in complete agreement with FCM and MSP in imprints of the same tumors. Apart from discriminating between diploid and hyperploid tumors, an attempt was made to determine peak DNA values of sarcomas analyzed in tissue sections. Peak DNA values, as defined by a minimum of 30% of the cells within a class width of DI 0.25, could be determined for 23 of 36 tumors. These peak DNA values correlated well with corresponding peaks obtained by FCM.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

本研究的目的是通过分析大量正常细胞群体的DNA数据,确定间充质组织切片中微分光光度法(MSP)DNA测量的二倍体上限。通过在印片标本中用MSP和流式细胞术(FCM)分析相同的肿瘤,测试了该二倍体上限对区分二倍体和超二倍体骨肉瘤的可靠性。组织切片中对照细胞的DNA中位数被赋予DNA指数(DI)1.0的任意值,表示二倍体DNA含量。确定每个正常细胞群体中DNA值超过DI 1.25(大于DI 1.25)的细胞比例。在组织切片中分析91个正常细胞群体时,DNA值超过DI 1.25的细胞的最大百分比为31%。该百分比被设定为二倍体上限。因此,细胞大于DI 1.25的百分比更高的肿瘤被归类为超二倍体。当我们应用该标准时,在组织切片中用MSP分析的36个肉瘤中有31个是超二倍体,这与同一肿瘤印片中的FCM和MSP完全一致。除了区分二倍体和超二倍体肿瘤外,还尝试确定组织切片中分析的肉瘤的峰值DNA值。对于36个肿瘤中的23个,可以确定峰值DNA值,其定义为在DI 0.25的类宽度内至少30%的细胞。这些峰值DNA值与通过FCM获得的相应峰值相关性良好。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验